echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > National hot discussion quick review answer! Behind the price killing, these 6 questions are worth thinking about!

    National hot discussion quick review answer! Behind the price killing, these 6 questions are worth thinking about!

    • Last Update: 2020-09-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guide: with the volume of procurement under the drug price reduction, can you deeply study the hidden tangles behind.
    , the third batch of national centralized belt procurement winning bid results have been settled, however, the third batch of collection brought about by the collection of heat without the slightest downward trend, netizens hot discussion.
    In the spirit of curiosity, learning mentality, the author combed some netizens comments, the simple threshold for collecting these comments is: first, there is a relatively broad representation;
    we have broadly divided these comments into six areas to begin some discussion.
    , on medicine and water who expensive tangle: "1, always say less than a bottle of mineral water prices."
    mineral water is also a windfall industry, if also the implementation of national mining negotiations, but also a few cents a bottle of things.
    2, 2020, there are still people who say not to eat cheaper than water medicine cliche, the price of water is 2.8 yuan / ton, even bottled mineral water, remove the cost of brand marketing and channels, into the national collection to try? Will the price be more expensive than the medicine? Isn't it time you didn't even drink water? Collection has also been carried out for so many years, a few years ago the winning medicine to eat the problem came? Collection change is the price is not quality, those who say not to take the winning medicine, as if they have not eaten before.
    3, on the drug collection, the house to engage in a collection to play? Analysis: The first comment perfectly explains the general value comparison between medicine and mineral water.
    but netizens still care about the question: Why put the price of medicine down to cheaper than mineral water? The first natural explanation that comes to mind is: First, it is easy to depress the market price of a bottle of mineral water, but it is not necessary;
    For example: beef, pork market prices such as the short-term rise fast, do not rule out there are hoarding odd, circulation control and other reasons, the natural reaction of the masses is that spitting slot meat prices are too expensive, temporarily buy less and eat less, not affect survival and health;
    to the stock market retail investors often make leeks as an example, but also can see that non-strategic buying behavior is often in a weak position.
    as for the house, can you do a collection? The main reason for the low feasibility is that the market and buyers are dispersed.
    the history of Japan's collection development.
    the near future, our country is the oldest country in the world with the largest population.
    Japan is seriously aging, our ageing population is several levels larger in size.
    model to measure the increasing aging of our country, can predict the severity of the medical burden.
    is now planning to take the purchase of more drugs, that is, early to win the depth of the strategy.
    II, on the price or shortage of raw materials: "1, raw materials for the king of the era has come, can not produce their own raw materials, there is no bottom gas to report prices, reported also white."
    2, do you really think the cost of producing drugs is high? Under the scale effect, the cost is very low.
    3, these suspected low prices of the fundamental do not understand the cost of drugs, chemical drugs is actually very low.
    before the high price of drugs people can not afford to be sick, now the price is low and said that the quality is not good, does the country not know the quality? 4, said that pharmaceutical companies can not survive, I would like to ask you really in the pharmaceutical factory? Or are they all well-paid vested interests in pharmaceutical ries? Pharmaceutical marketing costs, managers' high salaries, these costs are not added to the price of drugs? Support harvesting and cut off the high salaries of pharmaceutical ergonoes.
    5, believe that can maintain quality, but in case of API price fluctuations, can you guarantee quantity? After all, most of those ultra-low-cost drugs are commonly used for chronic diseases, once the market out of stock, will affect a large number of people.
    " analysis: take the on-site participation in the competition for metformin quotations, for example, these pharmaceutical companies have little ability to integrate raw materials preparations.
    , the first comment seems to be a false proposition.
    also pointed out that in the era of volume procurement, the integration of raw material preparations is the only way for pharmaceutical companies to bid efficiently.
    the author disagrees.
    main reasons for this is: First, can not participate in the volume of procurement of pharmaceutical companies look forward to expanding investment, which can have confidence, strength to go upstream to acquire raw materials? Imitation pharmaceutical production enterprises broke the ship encountered the top wind, is the mud pizza hard scalp across the river, itself is difficult to protect.
    Second, for raw material suppliers with volume procurement, strict industrial regulation and price supervision should be implemented immediately, not only to prevent further overcapacity, but also to prevent the price of RAW drugs from being raised by monopoly;
    As to why we should focus on monitoring the price or shortage of RAW drugs, because the quality risk of API, price changes on the survival and development of listed generic drugs and pharmaceutical companies, the stable operation of the procurement mechanism can play an important role in the bottom of the pot.
    At present, there is still a lack of long-term mechanism for the control and control of raw materials for raw materials and even more upstream chemical raw materials, for the purchase of drugs with volume as a breakthrough in the efficiency reform of the medical and health industry, the established basic policy, the status quo of such control capacity is worth worrying about, it is urgent to plan as soon as possible to supplement.
    , one-vote system, two-vote system, etc. are characteristics.
    3, on the volume of procurement may not be fair 1, the country' price is getting lower and lower, low enough to make you dare not imagine; 2, let multinational pharmaceutical companies feel the greatness of China's generic pharmaceutical enterprises so that domestic drug sales enterprises feel despair, so that the manufacturing industry outside the drug feel happy and balanced.
    3, in addition to Pfizer, Weisse other foreign enterprises are not involved, which is a very clear problem, after the collection of foreign enterprises by virtue of brand influence sales do not decline and rise, savings in health care funds or ultimately domestic enterprises to pay.
    4, foreign investment should not be marked, but also want to copy the second batch of collection loopholes brought about by the benefits, estimated that the abactuation this time to fall short, the third collection rules obviously blocked the loophole, can only do their own money market! 5, which has perfect reform, or these enterprises do their own, drug patent protection period after not taking the initiative to reduce prices.
    " analysis: the contradiction between regions in the implementation of volume procurement or online procurement of drug price gap.
    to the third batch of national drug collection efficiency, there is an imbalance between the national collection efficiency and the general situation in some places, and the national collection efficiency in the form of agreed procurement volume is also inadequate.
    first comment reflects the problem in the end does not exist, is not universal, worthy of special attention of relevant departments, this is the health insurance, medical procurement fine management content, related to the reform to see results.
    the contradictions inside and outside the volume procurement mechanism.
    In the previous drug national procurement, there are two multinational pharmaceutical companies in the participation in the procurement of the varieties of the volume of the winning, winning the bid, the result of the loser has obtained better economic benefits, in the industry to form a stronger public opinion response.
    , we see both the rationality of this: that is, doctors, patients, even if the expansion of out-of-the-way, out-of-the-way, but also the higher price of prescription, purchase of original drugs.
    as long as the original drug marketing without gold, not illegal, with the volume of procurement mechanism should be happy to see its success.
    Also see irrationality: that is, in the implementation cycle, we have some of the selected varieties with volume procurement failed to protect, landing well, so that it is not only the same varieties may continue to carry gold drug marketing impact, but also by similar varieties, with other types of drugs of adaptive disorders of the wanton impact.
    the latest implementation cycle after the third batch of national drugs, will this market failure and the loss of opportunities for the masses to choose be reduced and controlled? Not yet known.
    on the contradictions within the volume procurement mechanism.
    all the selected volume of procurement of pharmaceutical companies, products, barefoot pharmaceutical enterprises, products than the camp wearing shoes to harvest a sense of security.
    -band procurement mechanism has indeed helped these generic start-ups, cross-border enterprises a big busy, this phenomenon is a bit like the most serious outbreak of the new crown period, cross-border enterprises quickly switch to mask production.
    if the volume procurement mechanism is working and the benefits are good, cross-border players are moving into the future of generic drugs, not a joke.
    All the selected volume of procurement of pharmaceutical companies, products, shoe-wearing pharmaceutical companies, products have experienced a Nirvana, it seems that the strongman broken wrists, the reputation of return, in fact, in the past with gold sales in the era, I am afraid that individual Chinese medicine companies, products are also suspected of the original crime-style accumulation, now more to maintain market share or transition and fierce bidding.
    All selected with the volume of procurement of pharmaceutical companies, products than those who lost the bid to be more optimistic, easier, because the fall of the drug companies, products also have to pay for the level of price reduction, both in the volume of the introduction, elimination, but also in the full sales terminal pricing strategy readjustment.
    All selected with the volume of procurement of pharmaceutical enterprises, products, compared to the fall of the standard pharmaceutical enterprises, products are more likely to be in the volume of procurement escape birth day, low-capacity pharmaceutical companies, products can fully start production capacity, may remain in the generic industry survival.
    4, on the lack of affordable procurement with volume: "1, many varieties of the first and last position of the price is still a lot worse, then the first place to choose the province will be much cheaper than the last place of the province, will not cause cross-provincial drug purchase situation?" 2, feel to the pharmacy to buy medicine more and more expensive.
    3, brick-and-mortar pharmacies or online pharmacies business will catch fire, people who understand will still go to the drugstore at their own expense to buy.
    4, there is no strong retail terminal, for small businesses to survive.
    5, if the previous market is retail, it is estimated that the impact of collection is small.
    " analysis: With regard to the issues mentioned in article 1, the current reform is still in the process of deepening, and I believe that this imperfection will be erased as soon as possible.
    And under the third batch of national drug collection selection rules, the difference in prices between provinces on some varieties, even if present, is not or is rare and can lead to cross-provincial drug purchases.
    contrary, the national collection compared to the local volume procurement pilot has been included in the national scope, as long as the implementation of the start time, implementation of the landing effect between the efforts to achieve consistent, there is not much difference.
    we should compare from the historical vertical, the volume of drug transaction prices in various regions compared with the pre-harvest have a significant decline, this is the greatest achievement.
    the issue referred to in article 2 were also cases where direct intervention by the volume procurement mechanism was not necessary.
    drugs, especially medicines that are not targeted by health insurance or that are outside the scope of medical insurance.
    of indirect governance is to ensure the convenience and access of the masses to medical treatment and purchase medicines in medical and health institutions that use the quantity of medicines purchased.
    such as through online pharmacies, pharmaceutical e-commerce to improve the circulation of related drugs, the use of efficiency.
    on Article 4, we should pay special attention to the interests of selected enterprises, products and pharmaceutical e-commerce platform in volume procurement cooperation and game.
    pharmaceutical e-commerce is on the rise, as a new growth pole of the pharmaceutical business map, pharmaceutical e-commerce in the rapid expansion of the scale at the same time, there is no possibility of contracting the pharmaceutical business to do traditional control and marketing of the problem? The more effective detection method is: pharmaceutical e-commerce as a sales channel, the fee standard, the proportion is what? If pharmaceutical e-commerce providers provide value-added services such as warehousing and distribution, are the charges and proportions within a reasonable and proportionable range? Once the abnormally high situation, pharmaceutical e-commerce is the same as the exploitation of the vast number of small and medium-sized pharmaceutical industry enterprises, including generic pharmaceutical production enterprises, including the lack of marketing network, which is no different from a new environment, out of quasi-public welfare pharmaceutical commercial monopoly, representing a new type of market efficiency adjustment failure, and even has a large amount of procurement, theft of traffic and goodwill in the economy of the user's economic interests with gold suspicion.
    there may be such a phenomenon of windfall profits, profiteering expectations of pharmaceutical e-commerce to put forward a rebellious opinion: Why do we learn Lei Feng? What we're going to do is do business! In this regard, we put forward a tit-for-tat view: First, pharmaceutical production, circulation by the strong intervention of national policies, with the volume of procurement enterprises, drugs by "how much loss" is also evident, pharmaceutical e-commerce if they feel that adhere to the quasi-public welfare channel rate can not be received, there is freedom to give up do not do the business involved.
    Second, in the new two-vote, one-vote policy environment, there is no middleman, no difference is the general trend, pharmaceutical e-commerce services should take the cost plus commission approach, or imitate retail pharmacies to adopt a limited percentage of the way, but also let consumers enjoy the right to know where the money spent.
    , why study Lei Feng in Internet medicine, including pharmaceutical e-commerce? Because that's part of the business.
    example, the author went to the fruit and vegetable shop near home to buy vegetables, the boss saw the author holding a few things bought elsewhere is not good, specially gift a clean plastic bag.
    the fruit and vegetable shop is a little more expensive, but the boss often in these small things to make a good impression, won the customer affirmation.
    for example: some pharmaceutical e-commerce, insurance companies, medical institutions and medical institutions, such as desperately advertising to emphasize the public good, but in fact a bit of nonsense ingredients, especially when the mouth benefits are not true.
    in the above-mentioned for-profit or non-profit market entities to carry out business behavior, if on the basis of decision-making ability to adhere to the principles of social civilization, quasi-public welfare, more likely to become bigger and stronger.
    examples of similar success include: the supermarket earlier insisted on the lowest price in the same city, more than a few penalties;
    medical e-commerce can not be robbed of any bird.
    , on the volume of procurement ultra-low-cost operation: "1, buy family planning supplies?" Send Viagra.
    after the sale of sugar to send metformin, selling seafood to send non-cloth him, to run a fitness card to send amino glucose.
    2, seven brothers shot, the film A do not stay.
    west of the country, the whole country I am unique.
    two yuan and one point, love each other! Sacrifice point profit, sexual blessing adults.
    3, Brother Qi this is going to destroy the ED market ah.
    4, on theacid siding nafei, India imported raw materials as long as 3-400 yuan a kilogram, a gg of 4 cents, can do 100 Hawke pills 10, that is, 4 cents cost, of course, this is only a simple raw material cost, but no matter what, should not sell dozens of pieces, hundreds of pieces of a grain.
    5, for the late start of pharmaceutical companies is really a trace of life do not want to stay! "Analysis: About Siddana.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.